VBIZ.F Stock Overview
An investment holding company, engages in the provision of structure-based drug discovery services to biotechnology and pharmaceutical customers worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Viva Biotech Holdings Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.17 |
| 52 Week High | HK$0.17 |
| 52 Week Low | HK$0.05 |
| Beta | 1.19 |
| 11 Month Change | 22.02% |
| 3 Month Change | n/a |
| 1 Year Change | 20.14% |
| 33 Year Change | -75.42% |
| 5 Year Change | -72.87% |
| Change since IPO | -70.23% |
Recent News & Updates
Recent updates
Shareholder Returns
| VBIZ.F | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 0% | -7.2% | -1.2% |
| 1Y | 20.1% | 1.2% | 30.4% |
Return vs Industry: VBIZ.F exceeded the US Life Sciences industry which returned 2.9% over the past year.
Return vs Market: VBIZ.F underperformed the US Market which returned 29.7% over the past year.
Price Volatility
| VBIZ.F volatility | |
|---|---|
| VBIZ.F Average Weekly Movement | n/a |
| Life Sciences Industry Average Movement | 8.8% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: VBIZ.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine VBIZ.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 2,043 | Chen Cheney Mao | www.vivabiotech.com.cn |
Viva Biotech Holdings, an investment holding company, engages in the provision of structure-based drug discovery services to biotechnology and pharmaceutical customers worldwide. The company provides discovery biology services, including protein expression and purification, structural biology, hit discovery, bioassay, biomolecular interaction, and pharmacokinetics; chemistry services, such as medicinal and synthetic chemistry, analytical chemistry, purification preparation, and computer-aided drug design services, as well as offers chemical technology platforms; and antibody/biologics research and development services comprising recombinant protein expression platform, antibody discovery and affinity maturation, assay platform, antibody production and identification platform, and antigen-antibody structural resolution platform solutions. It also offers PROTAC/molecular glue services, including protein preparation and ternary complex structure determination, screening for molecule glues and novel E3 ligase ligands, PROTAC ternary complex kinetics, PROTAC degradation assays and ternary complex assays, PROTAC molecule design and synthesis, ADME & PK/PD studies of PROTAC molecules, and computer aided PROTAC design solutions; and XDC platforms, such as XDC conjugation and quality study, XDC chemistry research and development, and XDC functional studies.
Viva Biotech Holdings Fundamentals Summary
| VBIZ.F fundamental statistics | |
|---|---|
| Market cap | US$242.61m |
| Earnings (TTM) | -US$43.94k |
| Revenue (TTM) | US$275.67m |
0.9x
P/S Ratio-5,522x
P/E RatioIs VBIZ.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VBIZ.F income statement (TTM) | |
|---|---|
| Revenue | CN¥2.00b |
| Cost of Revenue | CN¥1.32b |
| Gross Profit | CN¥671.61m |
| Other Expenses | CN¥671.93m |
| Earnings | -CN¥318.00k |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.00015 |
| Gross Margin | 33.66% |
| Net Profit Margin | -0.016% |
| Debt/Equity Ratio | 39.8% |
How did VBIZ.F perform over the long term?
See historical performance and comparison